Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) EPS (Weighted Average and Diluted) (2019 - 2025)

Collegium Pharmaceutical (COLL) has 8 years of EPS (Weighted Average and Diluted) data on record, last reported at $0.84 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 211.11% year-over-year to $0.84; the TTM value through Sep 2025 reached $1.61, down 30.6%, while the annual FY2024 figure was $1.86, 44.19% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.84 in Q3 2025 per COLL's latest filing, up from $0.34 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.79 in Q2 2021 and bottomed at -$0.73 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.28, with a median of $0.34 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 465.0% in 2021, then surged 5200.0% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.73 in 2021, then surged by 71.23% to -$0.21 in 2022, then soared by 490.48% to $0.82 in 2023, then crashed by 56.1% to $0.36 in 2024, then skyrocketed by 133.33% to $0.84 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were $0.84 in Q3 2025, $0.34 in Q2 2025, and $0.07 in Q1 2025.